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INTRODUCTION:  The  rates  of pancreatic  cancer  development  in  the  early  stages  of  growth  remain  unclear;
but  it is  generally  believed  that  they  demonstrate  a rapid  degree  of progression.  There  is  evidence  to
suggest  that pancreatic  cancers  measuring  less  than  1  cm  demonstrate  better  survival  rates,  hence  it
is  clear  that  detecting  pancreatic  cancers  less  than  1 cm in size  is  of paramount  importance.  However,
to  date,  there  has  been  no  scientiﬁcally  adequate  research  to show  the  growth  rate  of small  pancreatic
cancers  less  than  1  cm  in  the  early  stages.
PRESENTATION  OF  CASE:  We  present  the case  of a 65-year-old  woman  whose  small  pancreatic  cancer  pos-
sibly  demonstrated  a slow  progressive  rate  as  it grew  to  an  invasive  carcinoma  measuring  1  cm diameter
from  over  the 29  months.
DISCUSSION: It is reasonable  to  assume  that  the progression  of some  pancreatic  cancers  until  1 cm  size,
can  take  up  to 29  months.  During  this  silent  period,  it is crucial  to detect  such  a small  pancreatic  cancer
by  means  of  the  initial  US  and  subsequent  EUS  and  ERCP.  It is clear,  therefore,  that  clinicians  have  to
be  aware  of  the  growth  rate  of  small  pancreatic  cancers  and  in  particular  high risk  patients  should  be
encouraged  to monitor  size  of  the  main  pancreatic  duct  by  means  of  US  on  regular basis.
CONCLUSION: This  could  give  better  outcomes  for pancreatic  cancer  patients.  Hopefully,  by detecting
these  lethal,  pancreatic  cancers  in  their  early  stages,  it will  give  us  an  extension  of  time  to  perform
effective  therapies.
gical  © 2013 Sur 
. Introduction
Pancreatic cancer is one of the major causes of malignant tumour
eaths worldwide. The incidence of pancreatic cancer has been
radually rising over the last two decades.1 There is no doubt that
he morbidity and mortality rates of pancreatic cancer patients are
igniﬁcantly high. Generally, it can be argued that the early stage
f other cancers such as stomach and colon have demonstrated
etter prognosis than the advanced stage. However, it has been
lluded to that the prognosis of even a small pancreatic cancer (T1,
ess than 2 cm)  does not have a better prognosis than the advanced
ancreatic cancer.2
In case of that T1 pancreatic cancers are divided into two cat-
gories: less than 1 cm tumour size (TSz) and tumour between 1
nd 2 cm.  Consequently, TSz < 1 group indicates a relative better
rognosis.3–5 Under the present circumstances, however, it might
e difﬁcult to detect such a small pancreas cancer, mainly due
o the absence of conspicuous symptoms and effective screening
trategies. In particular, more than 90% of pancreatic cancer mea-
uring 1 cm or less in diameter do not demonstrate any speciﬁc
ymptoms. Although there are limitations in detecting all small
ancreatic cancer, it is of vital importance to spare no effort to ﬁnd
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small pancreatic cancer. Therefore, it is important to investigate the
natural progression of the cancer, but it still remains unclear. Given
this case, it is reasonable to assume that the progression of some
pancreatic cancers until 1 cm size, can take up to 29 months.
2. Presentation of case
A  65-year-old female patient presented to our hospital without
any symptoms, after a private practitioner identiﬁed a rise of her
serum carcinoembryonic antigen 19-9 (CA19-9) level; which was
examined upon her request, albeit without any original symptoms.
There was  a moderate increase in tumour markers: CA19-9 52 U/ml
(normal range: 0–37 U/ml). No signs of pancreatitis or cholangi-
tis were detected. A transition of CA19-9 was demonstrated with
other critical events in Fig. 1. Enhanced CT, US, EGD and colonoscopy
(CS) were performed. However, ERCP was not performed, because
she simply denied an invasive procedure. Although, at the time,
the main pancreatic duct dilatation of 3.0 mm was  observed by CT
scan, no method of imaging was able to detect any malignant lesion
(Fig. 2a). After the clinical examinations and diagnostic imaging,
she returned to the private practitioner for her CA19-9 levels to be
monitored on a regular basis.
Open access under CC BY-NC-ND license.The patients consulted at our hospital, because her serum
CA19-9 rapidly increased during the last 11 months over a 29
months-period observation. Upon presentation, her current CA19-
9 levels were raised to 255.3 U/ml. Her other serum examination
-NC-ND license. 
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cig. 1. Her CA19-9 levels steadily kept above the threshold over the 18 months, and
hen sharply increased to 255.3 U/ml. After her surgery, the CA19-9 levels plum-
eted to within a normal limit.
esults were as follows: haemoglobin A1c (HbA1c) 6.6% (nor-
al range: 3.5–5.7%), fast blood sugar 144 mg/dl (normal range:
0–110 mg/dl), and normal range of serum amylase 46 U/ml (nor-
al range: 25–160 U/ml). CT and EUS demonstrated one solitary
esion measuring 9.5 mm at the pancreatic body superior to the
ortal vein (Figs. 2b and 3). Subsequent ERCP demonstrated an
rregular, abrupt stricture of the main pancreatic duct, accompa-
ied by a dilated main pancreatic duct in the body and tail of the
ancreas. Consequently, the mass was diagnosed as an adenocar-
inoma of the pancreas using brush cytology from the ERCP.
The  tumour had not inﬁltrated the portal vein, the superior
esenteric artery or vein, or the coeliac plexus of nerves, and was
ithout metastases. Therefore, a normal pancreaticoduodenec-
omy was performed without vesselplasty. Her clinical course was
table without complications, and she was discharged after 14 days
ig. 2. (a) CT scan demonstrated the main pancreatic duct dilatation (3.0 mm)  two
ears before resection of the pancreatic cancer. Yellow arrow head: the main pan-
reatic duct. (b) The enhanced CT scan revealed one solitary lesion measuring 10 mm
t the pancreatic body. Yellow arrow head: poor enhanced lesion, pancreatic cancer.
ed arrow: the dilated main pancreatic duct. (For interpretation of the references to
olour in this ﬁgure legend, the reader is referred to the web version of this article.)Fig. 3. EUS detected a low echoic lesion (Yellow arrow head) measuring 9.5 mm.
(For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
of hospitalisation. The patient is currently systemically well, with-
out any signs of tumour recurrence 12 months post-operatively.
According to the International Union Against Cancer (UICC)
and Japan Pancreas Society (JPS) classiﬁcation system, pathological
examination for the pancreas revealed an invasive ductal car-
cinoma, well differentiated, T1N0M0, Stage IA (UICC), tub1, Ph
1.1 × 1.0 cm,  pT1, pCH(−), pDU(−), pS(−), pRP(−), pPV(−), pA(−),
pPL(−), pN0/21, pPCM(−), pDPM(−), intermediate type, INF, ly0,
v0, ne0, mpd(−) (JPS) (Fig. 4). There was no evidence of IPMN or
other type of pancreatic malignant tumour. Ki 67 labelling index
was 35–40%. CA19-9 immunohistological examination also con-
ﬁrmed that the tumour ﬁrmly expressed CA19-9.
3. Discussion
Malignant pancreatic tumours can be divided into the following
categories: pancreatic cancer (invasive ductal carcinoma), IPMN,
mucinous cystic tumour (MCT), neuroendocrine tumours (NET),
and islet cell tumours. The most typical pancreatic cancer, being
invasive ductal carcinoma, is one of the worst malignant tumours
in terms of the patient outcomes mainly due to rapid growth rate,
difﬁculty in early diagnosis, and high resistance against the exist-
ing therapies. These factors lead to a median survival among all
patients of up to 1 year.6 However, these severe prognoses could
be improved by the early detection of pancreatic cancer. Less than
TSz 1 in diameter pancreatic cancer can indicate a possible bet-
ter prognosis. Generally, it has been pointed out that US and CT
reveal the dilatation of pancreatic duct in 57% of patients, while a
tumour mass is depicted in only 9% patients.7 CA19-9 levels indi-
cate a low sensitivity and speciﬁcity for TSz < 1 pancreatic cancers
(threshold value; 37 U/ml). However, ERCP, EUS, and EUS-FNA are
considered as the most sensitive procedures to detect small pancre-
atic cancers: these procedures potentially break the limit of clinical
detection. Yasuda et al. have shown that ERCP and EUS can detect
such lesions, even those cancers less than TSz < 1.8
Considering our case, CA19-9 monitoring was  clearly important
to diagnose a small pancreatic cancer. Difﬁculties remain in the full
utilisation of ERCP/EUS as they can lead to severe complications,
such as a severe pancreatitis. Given the poor prognosis of pancreatic
cancer, however, it can be argued that an aggressive application of
ERCP/EUS might be beneﬁcial in a case where CT or US detect minor
dilatation of the main pancreatic duct or cystic lesion in pancreas.
Furthermore, risk factors of pancreatic cancer, such as family cancer
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aig. 4. Pathological examination for the pancreas revealed an invasive ductal carcin
ion  of CA19-9. Ki 67 labelling index was 35–40%.
istory, hereditary pancreatitis, smoking etc., already have been
stablished. Among these high risk patients, it might be useful to
onitor CA19-9 and size of the main pancreatic duct by means of
S on regular basis.
From  a point of cell kinetics, this tumour growth pattern might
e compatible with the Gompertzian view where the initial small
umours grow slower, the following middle stage tumours grow
xponentially and reach the limit of clinical detection.9,10 During
he initial 18 months period, when CA19-9 level kept just above the
hreshold, the pancreatic cancer had not appeared invasive. Follow-
ng these at least 18 months, the tumour substantially had gained
nvasive ability. By means of CT scan reports, the doubling time
f pancreatic cancer, measuring from the initial range 13–47 mm
o the ﬁnal range 15–47 mm,  was estimated as 159 ± 67 (median,
44) days.11 However, the growth rate of small pancreatic cancers
as not become clear as a reliable study. Under the existing condi-
ion, Hisa et al.,12 have reported a case of a small pancreatic cancer
hich demonstrated a slow progression rate, with the tumour vol-
me  doubling time of 252 days, which is even longer than that
hown in the above study. Considering our case, it is reasonable
o believe that the pancreatic cancer already existed 29 months
go, because CA19-9 levels clearly decreased to within a normal
imit (8.9 IU/ml) after her surgery and subsequent immunohisto-
ogical examination revealed strong expression of CA19-9. The Ki
7 labelling index in this case was 35–40% which correspond to
he average of another previous report (28 ± 15%).13 It is important
o realise that the pancreatic cancer provides curable 29 months
eriod, albeit with normal pathological ﬁndings. Needless to say,
herefore, it is crucial to detect such a small pancreatic cancer dur-
ng this relatively long, asymptomatic silent period.
.  ConclusionThis report implicates that the development of pancreatic can-
er until TSz 1 could take up to 29 months in some cases. Slight
ilatation of the main pancreatic duct or cystic lesion in pancreas,
lbeit without tumour detection in US or enhanced CT scan, needseasuring 1.1 × 1.0 cm. Immunohistological examination conﬁrmed strong expres-
further  investigation using ERCP and EUS which could potentially
reveal pancreatic cancer in the less than TSz 1 period. This case
report is therefore vitally important as it increases clinical aware-
ness of the fact that early identiﬁcation of these lethal cancers might
give physicians an extension of time to intervene and perform pos-
sibly curative therapies which could lead to improved survival rates
in these patients. The present case may  shed light on the natural
history of the early pancreatic cancer.
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